Dean L. Schorno - Sep 14, 2022 Form 4 Insider Report for RIGEL PHARMACEUTICALS INC (RIGL)

Role
EVP & Chief Financial Officer
Signature
/s/ Dolly Vance (Attorney-in-Fact)
Stock symbol
RIGL
Transactions as of
Sep 14, 2022
Transactions value $
$0
Form type
4
Date filed
9/16/2022, 04:15 PM
Previous filing
Jan 26, 2022
Next filing
Dec 30, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RIGL Employee Stock Option (right to buy) Award $0 +81.3K $0.00 81.3K Sep 14, 2022 Common Stock 81.3K $2.00 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reporting person was granted an option with a performance-based condition with respect to 81,250 shares of common stock on January 23, 2019. Thus, the exercise price of this option is $2.00 (the closing price of the issuer's common stock on Nasdaq the date of grant). In light of the performance-based vesting condition of this grant, the grant was not reportable under Section 16 until the performance metric was satisfied. On September 14, 2022, it was determined that the performance metric had been met.
F2 The option was fully vested on September 14, 2022, the date the determination was made that the performance metric had been met.